Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 8, 2013, Pages 1992-2003

  Shaker, Mohamed E ^a,b   Ghani, Ayaz ^a   Shiha, Gamal E ^c   Ibrahim, Tarek M ^b   Mehal, Wajahat Z ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Apoptosis; Autophagy; Hepatic fibrosis; Histone deacetylase; Imatinib; Nilotinib

Indexed keywords

CASPASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; IMATINIB; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NILOTINIB;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; DNA FRAGMENTATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; AUTOPHAGY; BENZAMIDES; CASPASES; CELL LINE; CHEMOTAXIS; COLLAGEN TYPE I; CYCLOSPORINE; DNA FRAGMENTATION; HEPATIC STELLATE CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LIVER; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RATS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84877908566     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.02.033     Document Type: Article

References (46)

1. Friedman S.L. Hepatic fibrosis - overview. Toxicology 2008, 254:120-129.
2. Mehal W., Imaeda A. Cell death and fibrogenesis. Semin. Liver Dis. 2010, 30:226-231.
3. Kisseleva T., Brenner D.A. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:305-317.
4. Edinger A.L., Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 2004, 16:663-669.
5. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
6. Fengsrud M., Erichsen E.S., Berg T.O., Raiborg C., Seglen P.O. Ultrastructural characterization of the delimiting membranes of isolated autophagosomes and amphisomes by freeze-fracture electron microscopy. Eur. J. Cell Biol. 2000, 79:871-882.
7. Rubinsztein D.C., DiFiglia M., Heintz N., Nixon R.A., Qin Z.H., Ravikumar B., Stefanis L., Tolkovsky A. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005, 1:11-22.
8. Thoen L.F., Guimaraes E.L., Dolle L., Mannaerts I., Najimi M., Sokal E., van Grunsven L.A. A role for autophagy during hepatic stellate cell activation. J. Hepatol. 2011, 55:1353-1360.
9. Hernandez-Gea V., Ghiassi-Nejad Z., Rozenfeld R., Gordon R., Fiel M.I., Yue Z., Czaja M.J., Friedman S.L. Autophagy Releases Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human Tissues. Gastroenterology 2012, 142:938-946.
10. Rickmann M., Vaquero E.C., Malagelada J.R., Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology 2007, 132:2518-2532.
11. Deremer D.L., Ustun C., Nilotinib Natarajan K. a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther. 2008, 30:1956-1975.
12. Rhee C.K., Lee S.H., Yoon H.K., Kim S.C., Lee S.Y., Kwon S.S., Kim Y.K., Kim K.H., Kim T.J., Kim J.W. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 2011, 82:273-287.
13. Iyoda M., Shibata T., Hirai Y., Kuno Y., Akizawa T. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J. Am. Soc. Nephrol. 2011, 22:1486-1496.
14. Akhmetshina A., Dees C., Pileckyte M., Maurer B., Axmann R., Jungel A., Zwerina J., Gay S., Schett G., Distler O., Distler J.H. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008, 22:2214-2222.
15. Shaker M.E., Salem H.A., Shiha G.E., Ibrahim T.M. Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam. Clin. Pharmacol. 2011, 25:248-257.
16. Shaker M.E., Shiha G.E., Ibrahim T.M. Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis. Eur. J. Pharmacol. 2011, 670:593-600.
17. Shaker M.E., Zalata K.R., Mehal W.Z., Shiha G.E., Ibrahim T.M. Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. Toxicol. Appl. Pharmacol. 2011, 252:165-175.
18. Xu L., Hui A.Y., Albanis E., Arthur M.J., O'Byrne S.M., Blaner W.S., Mukherjee P., Friedman S.L., Eng F.J. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54:142-151.
19. Weiskirchen R., Gressner A.M. Isolation and culture of hepatic stellate cells. Methods Mol. Med. 2005, 117:99-113.
20. Ma J., Li F., Liu L., Cui D., Wu X., Jiang X., Jiang H. Raf kinase inhibitor protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells. Liver Int. 2009, 29:567-574.
21. Tanaka C., Yin O.Q., Sethuraman V., Smith T., Wang X., Grouss K., Kantarjian H., Giles F., Ottmann O.G., Galitz L., Schran H. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 2010, 87:197-203.
22. Hashmi A.Z., Hakim W., Kruglov E.A., Watanabe A., Watkins W., Dranoff J.A., Mehal W.Z. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G395-G401.
23. Biederbick A., Kern H.F., Elsasser H.P. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur. J. Cell Biol. 1995, 66:3-14.
24. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
25. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Semin. Liver Dis. 2001, 21:427-436.
26. Issa R., Williams E., Trim N., Kendall T., Arthur M.J., Reichen J., Benyon R.C., Iredale J.P. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001, 48:548-557.
27. Valenzuela M.T., Guerrero R., Nunez M.I., Ruiz De Almodovar J.M., Sarker M., de Murcia G., Oliver F.J. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21:1108-1116.
28. Fattman C.L., Delach S.M., Dou Q.P., Johnson D.E. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. Oncogene 2001, 20:2918-2926.
29. Katsuda K., Kataoka M., Uno F., Murakami T., Kondo T., Roth J.A., Tanaka N., Fujiwara T. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 2002, 21:2108-2113.
30. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gelinas C., Fuchs E.J., Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 2001, 3:409-416.
31. Jin F., Liu X., Zhou Z., Yue P., Lotan R., Khuri F.R., Chung L.W., Sun S.Y. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res. 2005, 65:6354-6363.
32. Liu Y., Wang Z., Kwong S.Q., Lui E.L., Friedman S.L., Li F.R., Lam R.W., Zhang G.C., Zhang H., Ye T. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J. Hepatol. 2011, 55:612-625.
33. Cho D.H., Jo Y.K., Hwang J.J., Lee Y.M., Roh S.A., Kim J.C. Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 2009, 274:95-100.
34. Wirawan E., Vande Walle L., Kersse K., Cornelis S., Claerhout S., Vanoverberghe I., Roelandt R., De Rycke R., Verspurten J., Declercq W., Agostinis P., Vanden Berghe T., Lippens S., Vandenabeele P. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010, 1:e18.
35. Daugas E., Nochy D., Ravagnan L., Loeffler M., Susin S.A., Zamzami N., Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 2000, 476:118-123.
36. van Loo G., Schotte P., van Gurp M., Demol H., Hoorelbeke B., Gevaert K., Rodriguez I., Ruiz-Carrillo A., Vandekerckhove J., Declercq W., Beyaert R., Vandenabeele P., Endonuclease G. a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ. 2001, 8:1136-1142.
37. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., Fulda S., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A., Kumar S., Lipton S.A., Lu X., Madeo F., Malorni W., Mehlen P., Nunez G., Peter M.E., Piacentini M., Rubinsztein D.C., Shi Y., Simon H.U., Vandenabeele P., White E., Yuan J., Zhivotovsky B., Melino G., Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012, 19:107-120.
38. Riedl S.J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5:897-907.
39. Vande Walle L., Van Damme P., Lamkanfi M., Saelens X., Vandekerckhove J., Gevaert K., Vandenabeele P. Proteome-wide Identification of HtrA2/Omi Substrates. J. Proteome Res. 2007, 6:1006-1015.
40. Li B., Hu Q., Wang H., Man N., Ren H., Wen L., Nukina N., Fei E., Wang G. Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death Differ. 2010, 17:1773-1784.
41. Lei W., Zhang K., Pan X., Hu Y., Wang D., Yuan X., Shu G., Song J. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int. J. Biochem. Cell Biol. 2010, 42:1489-1497.
42. Qin L., Han Y.P. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am. J. Pathol. 2010, 177:1915-1928.
43. Lechuga C.G., Hernandez-Nazara Z.H., Dominguez Rosales J.A., Morris E.R., Rincon A.R., Rivas-Estilla A.M., Esteban-Gamboa A., Rojkind M. TGF-beta1 modulates matrix metalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK, PI3-kinase, AKT, and p70S6k. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G974-G987.
44. Barter M.J., Pybus L., Litherland G.J., Rowan A.D., Clark I.M., Edwards D.R., Cawston T.E., Young D.A. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol. 2010, 29:602-612.
45. Rosato R.R., Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin. Ther. Targets 2005, 9:809-824.
46. Leist M., Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2001, 2:589-598.